Cefixime is indicated in the treatment of the following infections

• Typhoid fever
• Uncomplicated Urinary Tract Infections
• Otitis Media
• Pharyngitis and Tonsillitis,
• Acute Bronchitis and Acute Exacerbations of Chronic Bronchitis
• Uncomplicated gonorrhea 

URTI & ENT infection: e.g. Otitis media, sinusitis, tonsillitis and pharyngitis
LRTI: Pneumonia, acute bronchitis and acute exacerbation of chronic bronchitis
Genito–urinary tract infection: e.g. Cystitis, urethritis, pyelonephritis Gonorrhoea, acute uncomplicated gonococcal urethritis and cervicitis
Skin and soft tissue infections: e.g. Pyoderma, impetigo and furenculosis

SYPROX Tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:
Acute otitis media caused by Streptococcus pneumoniae , (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes.
Community-acquired pneumonia caused by Streptococcus pneumoniae or Haemophilus influenzae (including beta-lactamase-producing strains).
Acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (non-beta-lactamase-producing strains only), or Moraxella catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of Haemophilus influenzae .
Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).
Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes. Abscesses should be surgically drained as clinically indicated.
Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis .
Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus

Alphaken-C is indicated in

• Management of hypocalcaemia in patients undergoing dialysis for chronic renal failure. It has been shown to significantly reduce elevated parathyroid hormone (PTH) levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy
• Post-menopausal osteoporosis.
• Hypocalcaemia in hypoparathyroidism
• Parathyroidectomy
• Vitamin D dependent rickets
• Renal tubular osteocalcaemia
• Sporadic and oncogenic hypophosphatemic osteomalacia
• X-linked hypophosphatemic osteomalacia
• Osteomalacia in Malabsorption syndrome
• Hypocalcaemia and hypomagnesaemia after small bowel resection
• Osteoporosis in males
• Psoriasis

Diabetic Peripheral Neuropathy
Post Herpetic Neuralgia
Post Traumatic Neuralgia
Trigeminal Neuralgia
Low Back Pain

Ferfuse is indicated in the treatment of iron deficiency anemia in the following patients:

• non-dialysis dependent-chronic kidney disease (NDD-CKD) patients receiving an erythropoietin
• non-dialysis dependent-chronic kidney disease (NDD-CKD) patients not receiving an erythropoietin
• hemodialysis dependent-chronic kidney disease (HDD-CKD) patients receiving an erythropoietin
• peritoneal dialysis dependent-chronic kidney disease (PDD-CKD) patients receiving an erythropoietin.